{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T13:22:59Z","timestamp":1768742579219,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T00:00:00Z","timestamp":1464220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T00:00:00Z","timestamp":1464220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 AI 108296"],"award-info":[{"award-number":["R21 AI 108296"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["U01 MH-090325"],"award-info":[{"award-number":["U01 MH-090325"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["P01 MH-076388"],"award-info":[{"award-number":["P01 MH-076388"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01-MH082670"],"award-info":[{"award-number":["R01-MH082670"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["P01 MH-105303"],"award-info":[{"award-number":["P01 MH-105303"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01 MH-049981"],"award-info":[{"award-number":["R01 MH-049981"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["P30 MH097488"],"award-info":[{"award-number":["P30 MH097488"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12967-016-0904-y","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T04:22:33Z","timestamp":1464236553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV"],"prefix":"10.1186","volume":"14","author":[{"given":"Jeffrey S.","family":"Barrett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergei","family":"Spitsin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh","family":"Moorthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lackner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florin","family":"Tulic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Winters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwight L.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,26]]},"reference":[{"issue":"23","key":"904_CR1","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1212\/WNL.0b013e318200d727","volume":"75","author":"RK Heaton","year":"2010","unstructured":"Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology. 2010;75(23):2087\u201396.","journal-title":"Neurology"},{"issue":"2","key":"904_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11904-012-0118-8","volume":"9","author":"PW Hunt","year":"2012","unstructured":"Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV\/AIDS Rep. 2012;9(2):139\u201347.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"904_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/B978-0-12-407707-2.00002-3","volume":"119","author":"MM Lederman","year":"2013","unstructured":"Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119:51\u201383.","journal-title":"Adv Immunol"},{"issue":"11","key":"904_CR4","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/acn3.131","volume":"1","author":"JL McGuire","year":"2014","unstructured":"McGuire JL, Barrett JS, Vezina HE, Spitsin S, Douglas SD. Adjuvant therapies for HIV-associated neurocognitive disorders. Ann Clin Transl Neurol. 2014;1(11):938\u201352.","journal-title":"Ann Clin Transl Neurol."},{"key":"904_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1749-6632.2010.05826.x","volume":"1217","author":"SD Douglas","year":"2011","unstructured":"Douglas SD, Leeman SE. Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann N Y Acad Sci. 2011;1217:83\u201395.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"904_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.it.2009.03.006","volume":"30","author":"F Tuluc","year":"2009","unstructured":"Tuluc F, Lai JP, Kilpatrick LE, Evans DL, Douglas SD. Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol. 2009;30(6):271\u20136.","journal-title":"Trends Immunol"},{"issue":"Suppl 11","key":"904_CR7","first-page":"18","volume":"63","author":"R Hargreaves","year":"2002","unstructured":"Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry. 2002;63(Suppl 11):18\u201324.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"904_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1189\/jlb.0410200","volume":"89","author":"L Monaco-Shawver","year":"2011","unstructured":"Monaco-Shawver L, Schwartz L, Tuluc F, Guo CJ, Lai JP, Gunnam SM, et al. Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor. J Leukoc Biol. 2011;89(1):113\u201325.","journal-title":"J Leukoc Biol"},{"issue":"9","key":"904_CR9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.biopsych.2007.08.012","volume":"63","author":"DL Evans","year":"2008","unstructured":"Evans DL, Lynch KG, Benton T, Dube B, Gettes DR, Tustin NB, et al. Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus\/acquired immunodeficiency syndrome. Biol Psychiatry. 2008;63(9):899\u2013905.","journal-title":"Biol Psychiatry"},{"issue":"5383","key":"904_CR10","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1126\/science.281.5383.1640","volume":"281","author":"MS Kramer","year":"1998","unstructured":"Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998;281(5383):1640\u20135.","journal-title":"Science"},{"key":"904_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1196\/annals.1418.007","volume":"1144","author":"SD Douglas","year":"2008","unstructured":"Douglas SD, Lai JP, Tuluc F, Schwartz L, Kilpatrick LE. Neurokinin-1 receptor expression and function in human macrophages and brain: perspective on the role in HIV neuropathogenesis. Ann N Y Acad Sci. 2008;1144:90\u20136.","journal-title":"Ann N Y Acad Sci"},{"issue":"1\u20132","key":"904_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jneuroim.2004.08.022","volume":"157","author":"WZ Ho","year":"2004","unstructured":"Ho WZ, Douglas SD. Substance P and neurokinin-1 receptor modulation of HIV. J Neuroimmunol. 2004;157(1\u20132):48\u201355.","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"904_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0165-5728(01)00439-8","volume":"121","author":"Y Li","year":"2001","unstructured":"Li Y, Douglas SD, Song L, Sun S, Ho WZ. Substance P enhances HIV-1 replication in latently infected human immune cells. J Neuroimmunol. 2001;121(1\u20132):67\u201375.","journal-title":"J Neuroimmunol"},{"issue":"15","key":"904_CR14","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1097\/00002030-200110190-00019","volume":"15","author":"SD Douglas","year":"2001","unstructured":"Douglas SD, Ho WZ, Gettes DR, Cnaan A, Zhao H, Leserman J, et al. Elevated substance P levels in HIV-infected men. AIDS. 2001;15(15):2043\u20135.","journal-title":"AIDS"},{"issue":"3","key":"904_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1089\/aid.2007.0207","volume":"24","author":"SD Douglas","year":"2008","unstructured":"Douglas SD, Cnaan A, Lynch KG, Benton T, Zhao H, Gettes DR, et al. Elevated substance P levels in HIV-infected women in comparison to HIV-negative women. AIDS Res Hum Retrovir. 2008;24(3):375\u20138.","journal-title":"AIDS Res Hum Retrovir"},{"key":"904_CR16","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.2741\/1376","volume":"9","author":"KL Bost","year":"2004","unstructured":"Bost KL. Tachykinin-modulated anti-viral responses. Front Biosci. 2004;9:1994\u20138.","journal-title":"Front Biosci"},{"issue":"3","key":"904_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/aid.1996.12.195","volume":"12","author":"WZ Ho","year":"1996","unstructured":"Ho WZ, Cnaan A, Li YH, Zhao H, Lee HR, Song L, et al. Substance P modulates human immunodeficiency virus replication in human peripheral blood monocyte-derived macrophages. AIDS Res Hum Retrovir. 1996;12(3):195\u20138.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"18","key":"904_CR18","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1097\/QAD.0b013e3283405c33","volume":"24","author":"MM Manak","year":"2010","unstructured":"Manak MM, Moshkoff DA, Nguyen LT, Meshki J, Tebas P, Tuluc F, et al. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. AIDS. 2010;24(18):2789\u201396.","journal-title":"AIDS"},{"issue":"1","key":"904_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11481-006-9059-6","volume":"2","author":"X Wang","year":"2007","unstructured":"Wang X, Douglas SD, Lai JP, Tuluc F, Tebas P, Ho WZ. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. J Neuroimmune Pharmacol. 2007;2(1):42\u20138.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"7","key":"904_CR20","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1073\/pnas.071052298","volume":"98","author":"JP Lai","year":"2001","unstructured":"Lai JP, Ho WZ, Zhan GX, Yi Y, Collman RG, Douglas SD. Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes. Proc Natl Acad Sci USA. 2001;98(7):3970\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"904_CR21","unstructured":"Merck. Drug approval package: EMEND (Aprepitant) NDA #21-549. 2003."},{"issue":"2","key":"904_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/sj.npp.1300260","volume":"29","author":"MS Kramer","year":"2004","unstructured":"Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology. 2004;29(2):385\u201392.","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"904_CR23","doi-asserted-by":"publisher","first-page":"e24180","DOI":"10.1371\/journal.pone.0024180","volume":"6","author":"P Tebas","year":"2011","unstructured":"Tebas P, Tuluc F, Barrett JS, Wagner W, Kim D, Zhao H, et al. A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One. 2011;6(9):e24180.","journal-title":"PLoS One"},{"issue":"8","key":"904_CR24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1097\/QAD.0000000000000638","volume":"29","author":"P Tebas","year":"2015","unstructured":"Tebas P, Spitsin S, Barrett JS, Tuluc F, Elci O, Korelitz JJ, et al. Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. AIDS. 2015;29(8):931\u20139.","journal-title":"AIDS"},{"key":"904_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.11.003","author":"JM Greeson","year":"2015","unstructured":"Greeson JM, Gettes DR, Spitsin S, Dube B, Benton TD, Lynch KG, et al. The selective serotonin reuptake inhibitor citalopram decreases human immunodeficiency virus receptor and coreceptor expression in immune cells. Biol Psychiatry. 2015. doi: 10.1016\/j.biopsych.2015.11.003 .","journal-title":"Biol Psychiatry."},{"issue":"2","key":"904_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/0022-1759(90)90058-4","volume":"130","author":"NF Hassan","year":"1990","unstructured":"Hassan NF, Cutilli JR, Douglas SD. Isolation of highly purified human blood monocytes for in vitro HIV-1 infection studies of monocyte\/macrophages. J Immunol Methods. 1990;130(2):283\u20135.","journal-title":"J Immunol Methods"},{"issue":"2","key":"904_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0022-1759(86)90415-1","volume":"95","author":"NF Hassan","year":"1986","unstructured":"Hassan NF, Campbell DE, Douglas SD. Purification of human monocytes on gelatin-coated surfaces. J Immunol Methods. 1986;95(2):273\u20136.","journal-title":"J Immunol Methods"},{"issue":"10","key":"904_CR28","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1128\/JCM.41.10.4531-4536.2003","volume":"41","author":"S Palmer","year":"2003","unstructured":"Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41(10):4531\u20136.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"904_CR29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2010.05.009","volume":"76","author":"Y Shono","year":"2010","unstructured":"Shono Y, Jantratid E, Kesisoglou F, Reppas C, Dressman JB. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2010;76(1):95\u2013104.","journal-title":"Eur J Pharm Biopharm Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV"},{"issue":"11","key":"904_CR30","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.3109\/03639045.2012.737331","volume":"39","author":"DN Ridhurkar","year":"2013","unstructured":"Ridhurkar DN, Ansari KA, Kumar D, Kaul NS, Krishnamurthy T, Dhawan S, et al. Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties. Drug Dev Ind Pharm. 2013;39(11):1783\u201392.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1\u20132","key":"904_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ijpharm.2004.08.001","volume":"285","author":"Y Wu","year":"2004","unstructured":"Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm. 2004;285(1\u20132):135\u201346.","journal-title":"Int J Pharm"},{"issue":"3","key":"904_CR32","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jpba.2008.12.005","volume":"49","author":"D Wu","year":"2009","unstructured":"Wu D, Paul DJ, Zhao X, Douglas SD, Barrett JS. A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational NeuroAIDs research. J Pharm Biomed Anal. 2009;49(3):739\u201345.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"904_CR33","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1124\/dmd.32.2.246","volume":"32","author":"SE Huskey","year":"2004","unstructured":"Huskey SE, Dean BJ, Doss GA, Wang Z, Hop CE, Anari R, et al. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. Drug Metab Dispos. 2004;32(2):246\u201358.","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"904_CR34","first-page":"1367","volume":"27","author":"SE Huskey","year":"1999","unstructured":"Huskey SE, Luffer-Atlas D, Dean BJ, McGowan EM, Feeney WP, Chiu SH. Substance P receptor antagonist I: conversion of phosphoramidate prodrug after i.v. administration to rats and dogs. Drug Metab Dispos. 1999;27(11):1367\u201373.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"904_CR35","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1124\/dmd.31.6.785","volume":"31","author":"SE Huskey","year":"2003","unstructured":"Huskey SE, Dean BJ, Bakhtiar R, Sanchez RI, Tattersall FD, Rycroft W, et al. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab Dispos. 2003;31(6):785\u201391.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"904_CR36","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2165\/00003495-200464070-00013","volume":"64","author":"TM Dando","year":"2004","unstructured":"Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2004;64(7):777\u201394.","journal-title":"Drugs"},{"issue":"12","key":"904_CR37","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1517\/14656566.4.12.2279","volume":"4","author":"L Patel","year":"2003","unstructured":"Patel L, Lindley C. Aprepitant\u2014a novel NK1-receptor antagonist. Expert Opin Pharmacother. 2003;4(12):2279\u201396.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"904_CR38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.biopsych.2005.07.013","volume":"59","author":"M Keller","year":"2006","unstructured":"Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006;59(3):216\u201323.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"904_CR39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/JCP.0b013e31823608ca","volume":"31","author":"E Ratti","year":"2011","unstructured":"Ratti E, Bellew K, Bettica P, Bryson H, Zamuner S, Archer G, et al. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol. 2011;31(6):727\u201333.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"904_CR40","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.5665\/sleep.3208","volume":"36","author":"E Ratti","year":"2013","unstructured":"Ratti E, Carpenter DJ, Zamuner S, Fernandes S, Squassante L, Danker-Hopfe H, et al. Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia. Sleep. 2013;36(12):1823\u201330.","journal-title":"Sleep"},{"issue":"1","key":"904_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1517\/14728214.9.1.9","volume":"9","author":"RA Duffy","year":"2004","unstructured":"Duffy RA. Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs. 2004;9(1):9\u201321.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"2","key":"904_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2174\/1570162X12666140526120831","volume":"12","author":"JS Barrett","year":"2014","unstructured":"Barrett JS, Bajaj G, McGuire J, Wu D, Spitsin S, Moorthy G, et al. Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant. Curr HIV Res. 2014;12(2):121\u201331.","journal-title":"Curr HIV Res"},{"issue":"10","key":"904_CR43","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.biopsych.2004.02.007","volume":"55","author":"M Bergstrom","year":"2004","unstructured":"Bergstrom M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry. 2004;55(10):1007\u201312.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"904_CR44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1517\/14728214.11.1.137","volume":"11","author":"RM Navari","year":"2006","unstructured":"Navari RM, Province PS. Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006;11(1):137\u201351.","journal-title":"Expert Opin Emerg Drugs"},{"key":"904_CR45","unstructured":"EMA. EPAR scientific discussion 2006. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000527\/WC500026534.pdf ."},{"issue":"2","key":"904_CR46","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1523\/JNEUROSCI.05-02-00477.1985","volume":"5","author":"JN Crawley","year":"1985","unstructured":"Crawley JN, Ninan PT, Pickar D, Chrousos GP, Linnoila M, Skolnick P, et al. Neuropharmacological antagonism of the beta-carboline-induced \u201canxiety\u201d response in rhesus monkeys. J Neurosci. 1985;5(2):477\u201385.","journal-title":"J Neurosci"},{"issue":"6","key":"904_CR47","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1006\/phrs.1998.0455","volume":"39","author":"R Kumar","year":"1999","unstructured":"Kumar R, Palit G, Singh JR, Dhawan BN. Comparative behavioural effects of benzodiazepine and non-benzodiazepine anxiolytics in rhesus monkeys. Pharmacol Res. 1999;39(6):437\u201344.","journal-title":"Pharmacol Res"},{"issue":"5","key":"904_CR48","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/jac\/dkr595","volume":"67","author":"M Guzman-Fulgencio","year":"2012","unstructured":"Guzman-Fulgencio M, Jimenez JL, Berenguer J, Fernandez-Rodriguez A, Lopez JC, Cosin J, et al. Plasma IL-6 and IL-9 predict the failure of interferon-alpha plus ribavirin therapy in HIV\/HCV-coinfected patients. J Antimicrob Chemother. 2012;67(5):1238\u201345.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"904_CR49","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1038\/npp.2013.135","volume":"38","author":"MB Gatch","year":"2013","unstructured":"Gatch MB, Kozlenkov A, Huang RQ, Yang W, Nguyen JD, Gonzalez-Maeso J, et al. The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology. 2013;38(12):2373\u201384.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"904_CR50","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/jsr.12196","volume":"24","author":"AA Simen","year":"2015","unstructured":"Simen AA, Ma J, Svetnik V, Mayleben D, Maynard J, Roth A, et al. Efavirenz modulation of sleep spindles and sleep spectral profile. J Sleep Res. 2015;24(1):66\u201373.","journal-title":"J Sleep Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-016-0904-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-016-0904-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-016-0904-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-016-0904-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T04:21:36Z","timestamp":1718598096000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-016-0904-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,26]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1186\/s12967-016-0904-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,26]]},"assertion":[{"value":"4 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"148"}}